In the media

16 Mar 2020 -

The programme La Sexta Columna broadcasted by La Sexta has interviewed Patrick Aloy, head of the Structural Bioinformatics and Network Biology laboratory at IRB Barcelona, about the participation of his team in a European research project devoted to COVID-19. Aloy explains that the project will study the efficacy of more than 5000 drugs to fight this coronavirus. The scientist says, "If we do not get any results from these 5000 or 7000 compounds, we will have to widen the search and examine the million compounds that are available".

Link to: La Sexta Columna (minute 41: 10-42: 50)

   
<p>Manuel Serrano, head of the Cell Plasticity and Disease Laboratory at IRB Barcelona</p>
12 Mar 2020 -

Manuel Serrano, ICREA researcher and head of the Cell Plasticity and Disease Group at IRB Barcelona, has been interviewed on Radio 4´s programme De boca a orella. The interview was about ways to measure biological age. The scientist says that one of the techniques receiving most attention is the epigenetic clock. He goes on to explain that this is a “clock” present in our blood and that, combined with the study of other factors such as telomeres (the structures that form at the ends of chromosomes),  it serves to measure biological age. He goes on to say, ““Chromosomes are the structures in which lineal DNA is found. We have 23 chromosomes and their ends hold a repeated...

<p>Manuel Serrano, researcher at IRB Barcelona</p>
12 Mar 2020 -

The newspaper Entre Mayores has published an interview with Manuel Serrano, ICREA researcher and head of the Cell Plasticity and Disease Lab at IRB Barcelona, about senolytic compounds, which may be able to reverse the effects of aging.

Experimental research on animals to date has demonstrated that tissue health can be enhanced by eliminating senescent cells. This discovery has led many research groups to search for compounds with the capacity to selectively kill these cells. Although still in experimental stages, some drugs can remove these cells and, consequently, improve age-associated health conditions. “These drugs would in a certain way complete the tissue repair...

11 Mar 2020 -

The newspaper El Nacional has published an interview with Nuria López-Bigas, head of the Biomedical Genomics Lab at IRB Barcelona. López-Bigas explains that her lab work comprises computational analysis of the mutations present in tumours. According to this researcher, the most important focus of her work is “determining which of these mutations have led to the development of the tumour.”

Referring to her lab, she says “We work with an enormous number of data and the only way to analyse them is to design computer programmes that can look for the differences between genomes and identify the mutations”.  Thanks to these tools, it has been discovered that a single tumour can carry...

10 Mar 2020 -

The European Commission has awarded funding to 17 research projects in a special call announced to tackle the coronavirus. IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy,  is participating in one of these projects, together with other research centres. The project, called RiPCoN, will perform a computational study of the interactions between coronavirus and human cells, with the aim to identify drugs (already on the market or in trials)  that can halt the spread of the virus. 

Various media have reported on Spain’s participation  in 6 of the 17 projects chosen by the European Commission to advance and speed up research into the...

<p>Manuel Serrano, researcher at IRB Barcelona</p>
6 Mar 2020 -

The programme “El Balcó” broadcasted by the radio channel Cadena Ser has interviewed Manuel Serrano, ICREA researcher and head of the Cell Plasticity and Disease Lab at IRB Barcelona. The interview was about regenerative medicine, a kind of medicine that attempts to understand tissue regeneration mechanisms.  “The regenerative process is well described and it is known what happens. But there is little information about the mechanisms, genes and proteins involved,” says Serrano The researcher insists that “it is necessary to understand the process at the molecular level and to be able to manipulate it via pharmacological means. In processes involving defective repair, this...

<p>From left to right Silvia Benaiges, Jordi Ballart (Mayor of Terrassa) and Llorenç (Suma tu corazón)</p>
5 Mar 2020 -

Various media have reported on the presentation of the charity concert “Suma tu corazón”, which will be held in Terrassa on 20 March.  In 2019, IRB Barcelona launched its Metastasis Challenge” campaign. In the press conference, Sílvia Benaiges, head of Fundraising, Marketing and Communication at IRB Barcelona, explained that the objective of this campaign “is to create a social movement that involves everyone” and that supports research into cancer and metastasis.

The “Metastasis Challenge” is also backed by the initiatives of individual members of the public, the fundraising concert “Suma tu corazón” being an example. The bands Sa Parranda, the  Combo Aula de Música de Terrassa,...

<p>Manuel Serrano, researcher at IRB Barcelona</p>
4 Mar 2020 -

The journal The Scientist has published an interview with Manuel Serrano, ICREA researcher and head of the Cell Plasticity and Disease Lab at IRB Barcelona, about studies into cell aging done in recent years. In the 1950s, the scientist Leonard Hayflick did a series of studies in which he demonstrated that cells enter what is known as a “senescent” state. Initially, the scientific community rejected this concept, considering it irrelevant for living organisms. However, work done in later decades by researchers like Manuel Serrano has revealed the importance of cell senescence.  Serrano has observed that when cells are exposed to stress stimuli that would normally lead to some...

<p>Gloria Pascual, researcher at IRB Barcelona</p>
3 Mar 2020 -

EFE Salud’s radio programme El Bisturí has interviewed Gloria Pascual, researcher with IRB Barcelona’s Stem Cells and Cancer Laboratory at the Institute for Research in Biomedicine (IRB Barcelona), in relation to research by Joan Massagué, Director of the Sloan Kettering Institute, co-founder of IRB Barcelona and current Chair of its External Advisory Board. The study in question describes the origin of metastasis, a process by which cells leave the primary tumour, invade vital organs and seed a new tumour. Metastasis is responsible for 90% of cancer deaths.

The main goal of the research into this field is to discover new therapeutic targets specifically...

<p>Jordi Durán, researcher with the Metabolic Engineering and Diabetes Therapy Lab at IRB Barcelona</p>
26 Feb 2020 -

Betevé TV’s “Notícies Vespre” (Evening News) has broadcasted an interview with Jordi Durán, researcher with the Metabolic Engineering and Diabetes Therapy Lab at IRB Barcelona, about research into rare diseases. 

This lab carries out research into Lafora disease, a genetic neurodegenerative disorder. “The aim of this work is to explain why neurons degenerate and die. What happens is that glucose, a cellular product accumulates, and this causes the neurons to progressively die, causing neurodegeneration,” says Durán. 

Of note, all these discoveries being made about rare diseases can be extrapolated to more common diseases.

Link to:...